Mosapride

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Mosapride is a prokinetic 5-HT4 receptor agonist used to stimulate gastric motility.

Generic Name
Mosapride
DrugBank Accession Number
DB11675
Background

Mosapride is under investigation for the treatment and prevention of Postoperative Ileus and Gastric Peroral Endoscopic Pyloromyotomy (G-POEM). Mosapride has been investigated for the treatment and diagnostic of Constipation, Type 2 Diabetes, Functional Dyspepsia, Functional Constipation, and Epigastric Pain Syndrome, among others.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 421.9
Monoisotopic: 421.1568475
Chemical Formula
C21H25ClFN3O3
Synonyms
  • Mosapride

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Mosapride is combined with 1,2-Benzodiazepine.
AcenocoumarolThe risk or severity of adverse effects can be increased when Mosapride is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Mosapride.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Mosapride.
AclidiniumMosapride may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Mosapride.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mosapride.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Mosapride.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Mosapride.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Mosapride.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Mosapride CitrateMF497J489P112885-42-4HUZTYZBFZKRPFG-UHFFFAOYSA-N
International/Other Brands
Gasmotin (Dainippon Pharmaceutical Co., Ltd.)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
BONDIGEST COMPLEX® TABLETASMosapride Citrate (5 mg) + Pancrelipase (170 mg) + Simethicone (125 mg)Tablet, coatedOral2008-10-01Not applicableColombia flag

Categories

ATC Codes
A03FA09 — Mosapride
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminophenyl ethers. These are aromatic compounds that contain a phenol ether, which carries an amine group on the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Aminophenyl ethers
Direct Parent
Aminophenyl ethers
Alternative Parents
Aniline and substituted anilines / Phenylmethylamines / Phenoxy compounds / Benzylamines / Alkyl aryl ethers / Aralkylamines / Chlorobenzenes / Fluorobenzenes / Aryl chlorides / Aryl fluorides
show 12 more
Substituents
Alkyl aryl ether / Amine / Aminophenyl ether / Aniline or substituted anilines / Aralkylamine / Aromatic heteromonocyclic compound / Aryl chloride / Aryl fluoride / Aryl halide / Azacycle
show 29 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
I8MFJ1C0BY
CAS number
112885-41-3
InChI Key
YPELFRMCRYSPKZ-UHFFFAOYSA-N
InChI
InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27)
IUPAC Name
4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide
SMILES
CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1

References

General References
  1. Allen Pharma: Digesal (mosapride citrate) oral tablets [Link]
PubChem Compound
119584
PubChem Substance
347828043
ChemSpider
106780
BindingDB
94630
RxNav
135091
ChEBI
167204
ChEMBL
CHEMBL60889
Wikipedia
Mosapride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedTreatmentEpigastric Pain Syndrome / Functional Dyspepsia / Postprandial Distress Syndrome1
4Unknown StatusOtherColorectal Adenomas1
4Unknown StatusPreventionPostoperative paralytic ileus1
4Unknown StatusTreatmentChronic Constipation / Constipated Irritable Bowel Syndrome / Healthy Subjects (HS)1
4Unknown StatusTreatmentDiabetic Gastroparesis1
4Unknown StatusTreatmentType 2 Diabetes Mellitus1
3CompletedDiagnosticForeign Body Left During Endoscopic Examination1
3CompletedPreventionPrevention of Post Operative Ileus1
3CompletedTreatmentConstipation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionOral5 mg
Tablet, coatedOral10 mg
Tablet, film coatedOral5 mg
Tablet, film coatedOral5.28 mg
Tablet, coatedOral
TabletOral5 mg
Tablet, coatedOral5 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0218 mg/mLALOGPS
logP3.14ALOGPS
logP2.75ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)14.46ChemAxon
pKa (Strongest Basic)5.98ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area76.82 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity112.34 m3·mol-1ChemAxon
Polarizability43.79 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-0910400000-7b60d0e3ee1a9a5d92c9

Drug created on October 20, 2016 20:38 / Updated on May 07, 2021 21:07